Should pre-transplant MRD be used to guide treatment in AML?

During the EHA2021 Virtual Congress, the AML Hub spoke with Arnon Nagler, Tel Aviv University, Tel Aviv, IL. We asked, Should pre-transplant measurable residual disease (MRD) be used to guide treatment in AML?


Nagler begins by discussing the importance of MRD in AML treatment and transplantation. He highlights the significance of MRD in different settings as a prognosis factor and describes the result of his study presented at EHA2021. Finally, he outlines the current treatment landscape for transplants in relation to MRD status and makes recommendations for MRD-positive patients.


Hosted on Acast. See acast.com/privacy for more information.

More from AML Hub

  1. 03:36What were your highlights from ASH 2023?Apr 29, 2024
  2. 09:19What are the challenges associated with CAR T-cell therapy in patients with AML?Apr 25, 2024
  3. 07:27How might the MORPHO trial of gilteritinib impact clinical practice?Apr 08, 2024
  4. 11:49Risk stratification and guidelines in AML managementJan 08, 2024
  5. 06:04How are new fludarabine conditioning combinations impacting transplant outcomes?Apr 22, 2022
  6. 06:08Should pre-transplant MRD be used to guide treatment in AML?Jul 10, 2021
  7. 13:54Should pre-transplant MRD be used to guide treatment in AML?Jun 25, 2021
  8. 05:03Should pre-transplant MRD be used to guide treatment in AML?Jun 23, 2021
  9. 05:22Can HMA maintenance therapy improve eligibility for HSCT?Mar 17, 2021
  10. 16:07ALLG AMLM16: Does sorafenib plus intensive chemotherapy improve outcome in FLT3-ITD AML?Feb 02, 2021